Quantcast
Last updated on April 17, 2014 at 1:21 EDT

Latest Icos Stories

2014-02-26 16:26:01

DUBLIN, February 26, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/khhjl8/erectile) has announced the addition of the "Erectile Dysfunction Drugs Market - Forecast to 2019" [http://www.researchandmarkets.com/research/khhjl8/erectile ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The erectile dysfunction drugs market is expected to witness a decline across the globe, by the end of the...

2013-12-30 08:25:34

LONDON, Dec. 30, 2013 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Interstitial Cystitis (Painful Bladder Syndrome) Global Clinical Trials Review, H2, 2013Interstitial Cystitis (Painful Bladder Syndrome) Global Clinical Trials Review, H2, 2013 SummaryGlobalData's clinical trial report, "Interstitial Cystitis (Painful Bladder Syndrome) Global Clinical Trials Review, H2, 2013" provides data on the Interstitial Cystitis (Painful Bladder Syndrome)...

2013-11-01 08:27:46

NEW YORK, Nov. 1, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Analysts' Corner announced new research reports highlighting Pfizer Inc. (NYSE: PFE), Eli Lilly and Company (NYSE: LLY), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), and GlaxoSmithKline plc (NYSE: GSK). Today's readers may access these reports free of charge - including full price targets, industry analysis and...

2013-08-13 08:29:00

SEATTLE, Aug. 13, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, has announced that Michael A. Jacobsen is joining the company as vice president, finance and chief accounting officer. "Mike's experience leading finance teams responsible for the commercial launch of biopharmaceutical...

2012-12-04 16:28:19

MILPITAS, Calif., Dec. 4, 2012 /PRNewswire/ -- KLA-Tencor Corporation (NASDAQ: KLAC) today announced its next-generation light-emitting diode (LED) patterned wafer inspection tool, the ICOS WI-2280. Designed specifically for defect inspection and 2D metrology for LED applications, the ICOS WI-2280 also provides enhanced inspection capabilities and increased flexibility for microelectromechanical systems (MEMS) and semiconductor wafers spanning two inches to eight inches in size. The ICOS...

2012-10-16 07:27:04

PARMA, Italy, October 16, 2012 /PRNewswire/ -- Chiesi Group announces that it has successfully completed a Phase I trial of its inhaled PDE4 (phosphodiesterase 4) inhibitor, denoted CHF 6001, a new chemical entity developed for the treatment of inflammatory respiratory disorders, such as chronic obstructive pulmonary disease (COPD) and asthma. (Logo: http://photos.prnewswire.com/prnh/20121016/568014 ) The phase 1 study was conducted to evaluate safety,...

2012-06-21 02:26:32

SEATTLE, WA, June 21, 2012 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced the promotion of Scott Peterson, Ph.D., to Chief Scientific Officer.  Dr. Peterson joined Oncothyreon in August 2009 as Vice President, Clinical Development. "This promotion recognizes Scott's key role in advancing the scientific and preclinical support for both PX-866, our phosphatidylinositol-3-kinase (PI-3K) inhibitor currently in multiple Phase 2 clinical trials, and ONT-10, our...

2012-04-23 18:20:31

THOUSAND OAKS, Calif., April 23, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that George Rathmann, founding CEO of Amgen from 1980 to 1988 and board chairman until 1990, has passed away. Recruited by Bill Bowes, one of Amgen's founders, Rathmann possessed the kind of passion and charisma that helped build the company and attract world-class scientific talent. Regarded as one of the founding fathers of biotechnology, George had the vision to see how biotechnology could transform...

2011-10-17 11:40:00

SEATTLE, Oct. 17, 2011 /PRNewswire/ - Christopher Henney, Chairman of the Board of Oncothyreon Inc. (Nasdaq: ONTY) and of Anthera Pharmaceuticals (Nasdaq: ANTH) and Vice Chairman of the Board of Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC), received this year's Hall of Fame - special recognition of outstanding individual contributions award at the annual Biotech CEO Meeting at Laguna Beach. Henney, the co founder of Immunex, ICOS and Dendreon corporations was recognized for his...

2011-10-14 07:00:00

Annual Meeting Fosters Plans to Improve Patient Care Silver Spring, MD (PRWEB) October 14, 2011 The International CardiOncology Society (ICOS) and Cardiac Safety Research Consortium (CSRC) joined efforts last week at the Food and Drug Administrationâs (FDA) White Oak Facilities as part of an annual meeting to explore ways to integrate cardiology and oncology research, focusing on cardiac safety for patients undergoing cancer treatment....